» Articles » PMID: 12700230

Kinetic Instability of P53 Core Domain Mutants: Implications for Rescue by Small Molecules

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2003 Apr 18
PMID 12700230
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

Oncogenic mutations in the tumor suppressor protein p53 are found mainly in its DNA-binding core domain. Many of these mutants are thermodynamically unstable at body temperature. Here we show that these mutants also denature within minutes at 37 degrees C. The half-life (t(1/2)) of the unfolding of wild-type p53 core domain was 9 min. Hot spot mutants denatured more rapidly with increasing thermodynamic instability. The highly destabilized mutant I195T had a t(1/2) of less than 1 min. The wild-type p53-(94-360) construct, containing the core and tetramerization domains, was more stable, with t(1/2) = 37 min at 37 degrees C, similar to full-length p53. After unfolding, the denatured proteins aggregated, the rate increasing with higher concentrations of protein. A derivative of the p53-stabilizing peptide CDB3 significantly slowed down the unfolding rate of the p53 core domain. Drugs such as CDB3, which rescue the conformation of unstable mutants of p53, have to act during or immediately after biosynthesis. They should maintain the mutant protein in a folded conformation and prevent its aggregation, allowing it enough time to reach the nucleus and bind its sequence-specific target DNA or the p53 binding proteins that will stabilize it.

Citing Articles

Deciphering the safeguarding role of cysteine residues in p53 against HO-induced oxidation using high-resolution native mass spectrometry.

Peris-Diaz M, Krezel A, Barran P Commun Chem. 2025; 8(1):13.

PMID: 39814824 PMC: 11736120. DOI: 10.1038/s42004-024-01395-w.


Covalent Fragments Acting as Tyrosine Mimics for Mutant p53-Y220C Rescue by Nucleophilic Aromatic Substitution.

Klett T, Stahlecker J, Jaag S, Masberg B, Knappe C, Lammerhofer M ACS Pharmacol Transl Sci. 2024; 7(12):3984-3999.

PMID: 39698266 PMC: 11651176. DOI: 10.1021/acsptsci.4c00414.


Understanding the prion-like behavior of mutant p53 proteins in triple-negative breast cancer pathogenesis: The current therapeutic strategies and future directions.

Naeimzadeh Y, Tajbakhsh A, Fallahi J Heliyon. 2024; 10(4):e26260.

PMID: 38390040 PMC: 10881377. DOI: 10.1016/j.heliyon.2024.e26260.


Association of germline variants with somatic variants in breast tumors in a genome-wide study.

Tjader N, Beer A, Ramroop J, Tai M, Ping J, Gandhi T medRxiv. 2023; .

PMID: 38106140 PMC: 10723566. DOI: 10.1101/2023.12.06.23299442.


Targeting p53 pathways: mechanisms, structures, and advances in therapy.

Wang H, Guo M, Wei H, Chen Y Signal Transduct Target Ther. 2023; 8(1):92.

PMID: 36859359 PMC: 9977964. DOI: 10.1038/s41392-023-01347-1.